Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia

Haematologica

Volumn 95, Issue 6, 2010, Pages 936-941

  Elorza, Izaskun ^a   Palacio, Carlos ^b   Luis Dapena, Jose ^a   Gallur, Laura ^b   Sánchez de Toledo, José ^a   Díaz de Heredia, Cristina ^a  

^a Department of Pediatric Hematology and Oncology ^*  (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Hematopoietic stem cell transplantation; Minimal residual disease; Polymerase chain reaction

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUDARABINE; METHOTREXATE; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; FEMALE; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; PROGNOSIS; SURVIVAL RATE; WHOLE BODY RADIATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK FACTORS; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 77953177389     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.010843     Document Type: Article

References (29)

1. Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukaemia: the ALL-REZ BFM Study Group. J Clin Oncol. 2009;27(3):377-84.
2. Knechtli CJ, Goulden NJ, Hancock JP, Grandage VL, Harris El, Garland RJ, et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood. 1998;92(11):4072-9.
3. Krejci O, Van der Velden V, Bader P, Kreyenberg H, Goulden N, Hancock J, et al. Level of minimal residual disease prior to hematopoietic transplantation predicts prognosis in pediatric patients with acute lymphoblastic leukemia: a report of the Pre-BMT MRD study group. Bone Marrow Transplant. 2003;32(8):849-51.
4. Sramkova L, Muzikova K, Fronkova E, Krejci O, Sedlacek P, Formankova R, et al. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2007; 48(1):93-100.
5. Uzunel M, Jaksch M, Mattsson J, Ringden O. Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia. Br J Haematol. 2003;122(5):788-94.
6. Campana D, Coustan-Smith E, Janossy G. The immunologic detection of minimal residual disease in acute lymphoblastic leukemia. Blood. 1990;76(1):163-71.
7. Coustan-Smith E, Behm FG, Sánchez J, Boyett JM, Hancock ML, Raimondi SC, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet. 1998;351 (9102):550-1.
8. Kerst G, Kreyenberg H, Roth C, Well C, Dietz K, Coustan-Smith E, et al. Concurrent detection of minimal residual disease in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol. 2005;128(6):774-82.
9. Robillard N, Cavé H, Méchinaud F, Guidal C, Garnache-Ottou F, Rohrlich PS, et al. Four-color flow cytometry bypasses limitations of Ig/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia. Haematologica. 2005;90(11):1516-23.
10. Ortega JJ, Ribera JM, Oriol A, Bastida P, González ME, Calvo C, et al. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL. Haematologica. 2001;86(6):586-95.
11. Ribera JM, Ortega JJ, Oriol A, Bastida P, Calvo C, Pérez-Hurtado JM, et al. Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 Trial. J Clin Oncol. 2007;25(1):16-24.
12. Badell I, Muñoz A, Estella J, Fernández-Delgado R, Javier G, Verdeguer A, et al. Long-term results of two consecutive trials in childhood acute lymphoblastic leukaemia performed by the Spanish Cooperative Group for Childhood Acute Lymphoblastic Leukaemia Group (SHOP) from 1989 to 1998. Clin Transl Oncol. 2008;10(2):117-24.
13. Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry. 1999;38(4):139-52.
14. Nagler A, Condiotti R, Rabinowitz R, Schlesinger M, Nguyen M, Terstappen LW. Detection of minimal residual disease after bone marrow transplantation by multi-parametric flow cytometry. Med Oncol. 1999;16(3):177-87.
15. Dworzak MN, Gaipa G, Relei R, Veltroni M, Schumich A, Maglia O, et al. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: multiparametric assessment is feasible. Cytometry B Clin Cytom. 2008;74(6):331-40.
16. Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000;96(8):2691-6.
17. Szczepanski T. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? Leukemia. 2007; 21(4):622-6.
18. Campana D. Status of minimal residual disease testing in childhood haematological malignances. Br J Haematol. 2008;143(4): 481-9.
19. Ryan J, Quinn F, Meunier A, Boublikova L, Crampe M, Tewari P, et al. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches. Br J Haematol. 2009;144(1):107-15.
20. Malec M, van der Velden VH, Björklund E, Wijkhuijs JM, Soderhall S, Mazur J, et al. Analysis of minimal residual disease in childhood with acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangement and multicolor flow cytometric immunophenotyping. Leukemia. 2004;18(10):1630-6.
21. van der Velden VH, Joosten SA, Willemse MJ, van Wering ER, Lankester AW, van Dongen JJ, et al. Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukaemia. Leukemia 2001;15(9):1485-7.
22. Bader P, Hancock J, Kreyenberg H, Goulden NJ, Niethammer D, Oakhill A, et al. Minimal residual disease status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia 2002;16(9):1668-72.
23. van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ. Detection of minimal residual disease in hematologic malignancies by real-time PCR: principles, approaches and laboratory aspects. Leukemia. 2003;17(6): 1013-35.
24. Schilham MW, Balduzzi A, Bader P. Is there a role for minimal residual disease levels in the treatment of ALL patients who receive allogeneic stem cell? Bone Marrow Transplant. 2005;35 (Suppl 1):S49-52.
25. Vettenranta K, Saarinen-Pihkala UM, Cornish J, Steward C, Pamphilon D, Hori L, et al. Pediatric marrow transplantation for acute leukaemia using unrelated donors and T-repleted or deplete grafts: a case- matched analysis. Bone Marrow Transplant. 2000;25(4):395-9.
26. Uzunel M, Mattsson J, Jaksch M, Remberger M, Ringder O. The significance of graft-versus-host disease and pretrans- plantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. Blood. 2001;98(6): 1982-4.
27. Bader P, Klingebiel T, Schaudt A, Theurer-Mainka U, Handgretinger R, Lang P, et al. Prevention of relapse in paediatric patients with acute leukaemia and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single centre experience of 12 children. Leukemia. 1999;13(12):2079-86.
28. Choi SJ, Lee JH, Kim S, Lee YS, Seol M, Ryu SG, et al. Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study. Bone Marrow Transplant. 2005;36(2):163-9.
29. Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P, et al. Increasing mixed chimerism is an important prognostic factor for unfavourable outcome in children with acute lymphoblastic leukaemia after allogeneic stem-cell transplantation: possible role for pre-emptive Immuno therapy? J Clin Oncol. 2004;22(9): 1696-705.